Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.
The FDA has approved four oncology drugs thus far in May 2026. Credit: Ashley Grise / Shutterstock.com.
It has been a big month for the oncology space, underpinned by several US approvals in haematological and solid tumour indications – with BeOne Medicines, Taiho Oncology and Arvinas all securing the regulatory greenlight for their respective cancer drugs.
In the haematology space, the US Food and Drug Administration (FDA) approved Taiho’s combination acute myeloid leukaemia (AML) pill, Inqovi (decitabine/cedazuridine) plus venetoclax, in newly diagnosed adults aged 75 and up who cannot undergo induction chemotherapy. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
